Lipella Pharmaceuticals Launches Registry for Oral Lichen Planus Research
Lipella Pharmaceuticals, Inc. (NASDAQ: LIPO) has launched an Oral Lichen Planus (OLP) Patient Registry designed to improve research on this chronic condition. Oral Lichen Planus is a long-lasting inflammatory disease that affects the mucous membranes in the mouth. It is characterized by symptoms such as burning pain, white patches, swollen tissue, and open sores. Approximately 6 million Americans suffer from OLP, and unfortunately, there are currently no FDA-approved treatments available for this condition.
The new registry platform aims to support research initiatives and accelerate the development of new treatment options. This online resource provides vital information about investigational studies related to LP-310, an oral rinse formulation based on Lipella’s lead candidate, LP-10, which also targets hemorrhagic cystitis. Importantly, LP-310 has received FDA approval for clinical evaluation to assess its effectiveness in treating OLP.
Research Advancements in Oral Lichen Planus
Dr. Michael Chancellor, Chief Medical Officer of Lipella Pharmaceuticals, expressed excitement about the launch of the OLP Patient Registry. He stated, "We are pleased to introduce this critical registry with the aim of increasing awareness and accelerating research into Oral Lichen Planus, a condition that urgently requires effective treatment options for millions of sufferers worldwide." The registry is an essential tool for collecting patient data, which is crucial for advancing OLP research.
Furthermore, CEO Dr. Jonathan Kaufman emphasized the strong interest from various stakeholders in improving patient outcomes and coordinating research efforts within the OLP community. He remarked, "This registry aligns with our mission to enhance treatment approaches for this challenging condition, providing a solid foundation for future therapeutic advancements." The registry is expected to foster strong collaborations as researchers and healthcare professionals engage with it.
Understanding Oral Lichen Planus
Oral Lichen Planus is recognized as a debilitating condition primarily marked by chronic oral mucosal lesions. These lesions can cause significant discomfort and complicate daily activities such as eating and speaking. The limitations of current treatment options highlight the urgent need for innovative solutions.
Lipella Pharmaceuticals is actively working to fill this gap, as demonstrated by its Phase 2a clinical trial of LP-310. This novel liposomal-tacrolimus oral rinse is a reformulated version of LP-10 and is being specifically assessed for its potential to effectively manage the symptoms of Oral Lichen Planus.
Accessing the Oral Lichen Planus Patient Registry
The Oral Lichen Planus Patient Registry is now live, allowing patients and healthcare providers to actively participate in research efforts. This initiative reflects Lipella's dedication to addressing treatment gaps and promoting innovation in patient care. Detailed information about the LP-310 clinical trial is available, encouraging interested individuals to seek further details.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative drug therapies by reformulating existing generic medications and optimizing them for new clinical uses. The company primarily targets diseases that present significant unaddressed morbidity and mortality, especially where no approved therapies exist. In December 2022, Lipella successfully completed its initial public offering, marking a significant milestone in its growth journey.
Contact Information
For inquiries, please reach out to Dr. Jonathan Kaufman, CEO of Lipella Pharmaceuticals, at Info@Lipella.com or call 1-412-894-1853. Additionally, Jeff Ramson from PCG Advisory is available at jramson@pcgadvisory.com or 646-863-6893 for further assistance.
Frequently Asked Questions
What is Oral Lichen Planus?
Oral Lichen Planus is a chronic inflammatory condition that affects the mucous membranes inside the mouth, leading to symptoms such as burning sensations and white patches.
Why was the Patient Registry established?
The registry was created to enhance research efforts and collect patient data, ultimately aiding in the development of effective treatment solutions for Oral Lichen Planus.
What is LP-310?
LP-310 is an oral rinse derived from Lipella's lead candidate, LP-10, which is currently undergoing clinical trials to evaluate its effectiveness in treating Oral Lichen Planus.
How can I participate in the registry?
Individuals interested in participating can access the Oral Lichen Planus Patient Registry online, where they will find further details and resources.
Who can I contact for more information?
For additional information, you can contact Dr. Jonathan Kaufman at Lipella Pharmaceuticals or reach out to Jeff Ramson from PCG Advisory for further assistance.
